School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Jonathon Cohen MD, MS

  • Department of Hematology and Medical Oncology
    Professor
  • (404) 778-2214
  • jonathon.cohen@emory.edu
Head shot of Jonathon Cohen

Academic Appointment

  • Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

  • MS from The Ohio State University
  • MD from University of Florida College of Medicine
  • BA from Emory University

Research

Focus

  • I aim to develop a program in clinical investigation for B-cell malignancies, specifically aggressive B-cell non-Hodgkins lymphoma. I plan to investigate novel prognostic markers and develop early phase clinical trials both within the institution and through the cooperative group to improve outcomes for patients with Hodgkins and non-Hodgkins lymphoma.

Publications

  • Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 25 Page(s): e183 - e199.e8
    04/01/2025 Authors: Nastoupil LJ; Andersen CR; Ayers A; Wang Y; Habermann TM; Chihara D; Kahl BS; Link BK; Koff JL; Cohen JB
  • Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
    Am J Hematol Volume: 100 Page(s): 606 - 615
    04/01/2025 Authors: Yamshon S; Koff JL; Larson MC; Kahl BS; Casulo C; Lossos IS; Haddadi S; Stanchina M; Chihara D; Ayers A
  • Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.
    Blood Cancer J Volume: 15 Page(s): 43
    03/26/2025 Authors: Karmali R; Shouse G; Torka P; Moyo TK; Romancik J; Barta SK; Bhansali R; Cohen JB; Shah NN; Zurko J
  • Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.
    Blood Adv Volume: 9 Page(s): 1013 - 1023
    03/11/2025 Authors: Day JR; Larson MC; Durani U; Koff JL; Wang Y; Habermann TM; Lossos IS; Nastoupil LJ; Strouse C; Chihara D
  • Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
    Haematologica Volume: 110 Page(s): 92 - 102
    01/01/2025 Authors: Shah NN; Wang M; Roeker LE; Patel K; Woyach JA; Wierda WG; Ujjani CS; Eyre TA; Zinzani PL; Alencar AJ
  • Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial.
    EClinicalMedicine Volume: 78 Page(s): 102959
    12/01/2024 Authors: Friedberg JW; Brady MT; Strawderman M; Kahl BS; Lossos IS; Cohen JB; Reagan PM; Casulo C; Averill BL; Baran A
  • Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation.
    Blood Adv Volume: 8 Page(s): 5458 - 5466
    11/12/2024 Authors: Epperla N; Huang Y; Cashen AF; Vaughn JL; Hanel W; Badar T; Barta SK; Caimi PF; Sethi TK; Reddy N
  • Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis.
    Blood Volume: 144 Page(s): 2063 - 2066
    11/07/2024 Authors: Abro B; Maurer MJ; Habermann TM; Burack WR; Chapman JR; Cohen JB; Friedberg JW; Inghirami G; Kahl BS; Larson MC
  • Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation.
    Transplant Cell Ther Volume: 30 Page(s): 832 - 843
    09/01/2024 Authors: Iqbal M; Kumar A; Dreger P; Chavez J; Sauter CS; Sureda AM; Bachanova V; Maziarz RT; Dreyling M; Smith SM
  • Is rituximab retro in mantle cell lymphoma?
    Blood Volume: 144 Page(s): 241 - 243
    07/18/2024 Authors: Ryan CE; Cohen JB
  • Defining primary refractory large B-cell lymphoma.
    Blood Adv Volume: 8 Page(s): 3402 - 3415
    07/09/2024 Authors: Bock AM; Mwangi R; Wang Y; Khurana A; Maurer MJ; Ayers A; Kahl BS; Martin P; Cohen JB; Casulo C
  • Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma.
    Haematologica Volume: 109 Page(s): 2177 - 2185
    07/01/2024 Authors: Maurer MJ; Casulo C; Larson MC; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P
  • Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.
    Blood Adv Volume: 8 Page(s): 2327 - 2331
    05/28/2024 Authors: Melody M; Epperla N; Shouse G; Romancik J; Allen P; Moyo TK; Kenkre V; Ollila T; Fitzgerald L; Hess B
  • Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.
    Blood Adv Volume: 8 Page(s): 2592 - 2599
    05/28/2024 Authors: Karmali R; Machhi R; Epperla N; Shouse G; Romancik J; Moyo TK; Kenkre V; Ollila TA; Fitzgerald L; Hess B
  • The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
    Am J Hematol Volume: 99 Page(s): 408 - 421
    03/01/2024 Authors: Cerhan JR; Maurer MJ; Link BK; Feldman AL; Habermann TM; Jaye DL; Burack WR; McDonnell TJ; Vega F; Chapman JR
  • Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma.
    Transplant Cell Ther Volume: 30 Page(s): 241.e1 - 241.e8
    02/01/2024 Authors: Munoz J; Flinn IW; Cohen JB; Sachs J; Exter B; Ranger A; Harris P; Payumo F; Nath R; Hamadani M
  • Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
    Br J Haematol Volume: 204 Page(s): 160 - 170
    01/01/2024 Authors: Ramsower CA; Rosenthal A; Robetorye RS; Mwangi R; Maurer M; Villa D; McDonnell T; Feldman A; Cohen JB; Habermann T
  • A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
    Ann Hematol Volume: 103 Page(s): 185 - 198
    01/01/2024 Authors: Merryman RW; Redd RA; Freedman AS; Ahn IE; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen ED; Kim AI
  • Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
    Blood Adv Volume: 7 Page(s): 7393 - 7401
    12/26/2023 Authors: Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang M; Cohen JB; Churnetski M
  • SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
    Clin Lymphoma Myeloma Leuk Volume: 23 Page(s): 861 - 865
    12/01/2023 Authors: Nayak RK; Gerber D; Zhang C; Cohen JB
  • Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
    Haematologica Volume: 108 Page(s): 3433 - 3437
    12/01/2023 Authors: Crombie JL; Jacobson CA; Redd R; Shouse G; Herrera AF; Chow VA; Gauthier J; Mullane E; Cahill K; Kline J
  • Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
    J Hematol Oncol Volume: 16 Page(s): 111
    11/09/2023 Authors: Epperla N; Feng L; Shah NN; Fitzgerald L; Shah H; Stephens DM; Lee CJ; Ollila T; Shouse G; Danilov AV
  • TRES, a validated three-factor comorbidity score, is associated with survival in older patients with mantle cell lymphoma.
    Haematologica Volume: 108 Page(s): 3110 - 3114
    11/01/2023 Authors: Gordon MJ; Bond DA; Kittai AS; Amirmokhtari N; Steinbrunner A; Huffman A; Orellana-Noia V; Shouse G; Cohen JB; Phillips T
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
    Blood Adv Volume: 7 Page(s): 6266 - 6274
    10/24/2023 Authors: Ansell SM; Brckelmann PJ; von Keudell G; Lee HJ; Santoro A; Zinzani PL; Collins GP; Cohen JB; de Boer JP; Kuruvilla J
  • Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
    Volume: 23 Page(s): S442 - S443
    09/01/2023 Authors: Nastoupil LJ; Andersen C; Ayers A; Wang Y; Habermann TM; Chihara D; Kahl BS; Link BK; Ayyappan S; Cohen JB
  • Recent approval of pirtobrutinib for mantle cell lymphoma.
    Clin Adv Hematol Oncol Volume: 21 Page(s): 431 - 433
    08/01/2023 Authors: Cohen JB
  • A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
    Blood Adv Volume: 7 Page(s): 2983 - 2993
    07/11/2023 Authors: Sawalha Y; Goyal S; Switchenko JM; Romancik JT; Kamdar M; Greenwell IB; Hess BT; Isaac KM; Portell CA; Mejia Garcia A
  • Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
    N Engl J Med Volume: 389 Page(s): 33 - 44
    07/06/2023 Authors: Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS
  • Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
    Blood Adv Volume: 7 Page(s): 2657 - 2669
    06/27/2023 Authors: Zurko J; Nizamuddin I; Epperla N; David K; Cohen JB; Moyo TK; Ollila T; Hess B; Roy I; Ferdman R
  • Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
    Blood Adv Volume: 7 Page(s): 2287 - 2296
    06/13/2023 Authors: Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M
  • Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies.
    Blood Adv Volume: 7 Page(s): 2459 - 2462
    06/13/2023 Authors: Chang A; Koff JL; Lai L; Orellana-Noia VM; Surati M; Leal AMK; Ellis ML; Wali B; Moreno A; Linderman SL
  • 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
    Hematol Oncol Volume: 41 Suppl 2 Page(s): 430 - 432
    06/01/2023 Authors: Bock AM; Mwangi R; Wang Y; Khurana A; Maurer MJ; Ayers A; Kahl B; Martin P; Cohen J; Casulo C
  • Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma.
    Blood Volume: 141 Page(s): 1888 - 1893
    04/13/2023 Authors: Alderuccio JP; Reis IM; Koff JL; Larson MC; Chihara D; Zhao W; Haddadi S; Habermann TM; Martin P; Chapman JR
  • A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
    Cancers (Basel) Volume: 15
    02/24/2023 Authors: Hanel W; Shindiapina P; Bond DA; Sawalha Y; Epperla N; Voorhees T; Welkie RL; Huang Y; Behbehani GK; Zhang X
  • Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
    J Clin Oncol Volume: 41 Page(s): 541 - 554
    01/20/2023 Authors: Martin P; Cohen JB; Wang M; Kumar A; Hill B; Villa D; Switchenko JM; Kahl B; Maddocks K; Grover NS
  • Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
    Blood Adv Volume: 7 Page(s): 88 - 91
    01/10/2023 Authors: Epperla N; Zhao Q; Chowdhury SM; Shea L; Moyo TK; Reddy N; Sheets J; Weiner DM; Geethakumari PR; Kandarpa M
  • Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
    Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
    12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA
  • Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial.
    Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): e1084 - e1091
    12/01/2022 Authors: Romancik JT; Chen Z; Allen PB; Waller EK; Valla K; Colbert A; Rosand C; Palmer AF; Flowers CR; Cohen JB
  • EXABS-205-MCL Immunotherapeutic Options for Patients with MCL Who Progress on BTK Inhibitors.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S97 - S98
    10/01/2022 Authors: Cohen JB
  • MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S394 - S395
    10/01/2022 Authors: Cohen JB; Shah NN; Alencar AJ; Gerson JN; Patel MR; Fakhri B; Jurczak W; Tan XN; Lewis KL; Fenske T
  • ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S381
    10/01/2022 Authors: Orellana-Noia V; Reed D; McCook A; Sen J; Barlow C; Malecek M-K; Watkins M; Kahl B; Spinner M; Advani R
  • CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S268 - S269
    10/01/2022 Authors: Coombs CC; Pagel JM; Shah NN; Lamanna N; Munir T; Lech-Maranda E; Eyre TA; Woyach JA; Wierda WG; Cheah CY
  • CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S281 - S282
    10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
  • Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
    Volume: 22 Page(s): S281 - S282
    10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
  • Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
    Volume: 22 Page(s): S381 - S381
    10/01/2022 Authors: Orellana-Noia V; Reed D; McCook A; Sen J; Barlow C; Malecek M-K; Watkins M; Kahl B; Spinner M; Advani R
  • Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study
    Volume: 22 Page(s): S268 - S269
    10/01/2022 Authors: Coombs CC; Pagel JM; Shah NN; Lamanna N; Munir T; Lech-Maranda E; Eyre TA; Woyach JA; Wierda WG; Cheah CY
  • Immunotherapeutic Options for Patients with MCL Who Progress on BTK Inhibitors
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 22 Page(s): S97 - S98
    10/01/2022 Authors: Cohen JB
  • Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemia.
    J Clin Invest Volume: 132
    09/15/2022 Authors: Chang A; Sholukh AM; Wieland A; Jaye DL; Carrington M; Huang M-L; Xie H; Jerome KR; Roychoudhury P; Greninger AL
  • Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol Volume: 40 Page(s): 3020 - 3031
    09/10/2022 Authors: Chang A; Akhtar A; Linderman SL; Lai L; Orellana-Noia VM; Valanparambil R; Ahmed H; Zarnitsyna VI; McCook-Veal AA; Switchenko JM
  • Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis.
    Blood Adv Volume: 6 Page(s): 4413 - 4423
    08/09/2022 Authors: Luan D; Fatola T; Toure A; Flowers CR; Link B; Friedberg JW; Cohen JB; Kahl B; Lossos IS; Nastoupil L
  • SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 22 Page(s): 557 - 565
    08/01/2022 Authors: Romancik JT; Gerber DG; Zhuang T; Cohen JB
  • A multicenter, real-world analysis of primary central nervous system lymphoma in those with and without human immunodeficiency virus.
    EJHaem Volume: 3 Page(s): 734 - 738
    08/01/2022 Authors: Dittus C; Grover N; Sethi T; Cohen JB; Voloschin A; Rabadey J; Tan X; Beaven A; Park SI
  • Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
    J Hematol Oncol Volume: 15 Page(s): 96
    07/16/2022 Authors: Epperla N; Zhao Q; Chowdhury SM; Shea L; Moyo TK; Reddy N; Sheets J; Weiner DM; Geethakumari PR; Kandarpa M
  • A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
    Leuk Lymphoma Volume: 63 Page(s): 1750 - 1753
    07/01/2022 Authors: Bond DA; Huang Y; Christian BA; Jaglowski S; Benson D; Alinari L; Baiocchi RA; Cohen JB; Blum KA; Maddocks KJ
  • Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
    Lancet Haematol Volume: 9 Page(s): e289 - e300
    04/01/2022 Authors: Casulo C; Larson MC; Lunde JJ; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P
  • Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study
    Volume: 197 Page(s): 97 - 101
    04/01/2022 Authors: Mato A; Pagel J; Coombs C; Shah N; Lamanna N; Munir T; Lech-Maranda E; Eyre T; Woyach J; Wierda W
  • Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
    Blood Adv Volume: 6 Page(s): 1490 - 1498
    03/08/2022 Authors: Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
  • Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
    Blood Volume: 139 Page(s): 1330 - 1339
    03/03/2022 Authors: Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW
  • Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
    Blood Adv Volume: 6 Page(s): 1350 - 1360
    02/22/2022 Authors: Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J
  • Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
    Blood Volume: 139 Page(s): 413 - 423
    01/20/2022 Authors: Orellana-Noia VM; Reed DR; McCook AA; Sen JM; Barlow CM; Malecek M-K; Watkins M; Kahl BS; Spinner MA; Advani R
  • Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
    Blood Adv Volume: 5 Page(s): 5179 - 5189
    12/14/2021 Authors: Bond DA; Switchenko JM; Villa D; Maddocks K; Churnetski M; Gerrie AS; Goyal S; Shanmugasundaram K; Calzada O; Kolla B
  • ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
    Bone Marrow Transplant Volume: 56 Page(s): 2911 - 2921
    12/01/2021 Authors: Munshi PN; Hamadani M; Kumar A; Dreger P; Friedberg JW; Dreyling M; Kahl B; Jerkeman M; Kharfan-Dabaja MA; Locke FL
  • Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation.
    Br J Haematol Volume: 195 Page(s): 757 - 763
    12/01/2021 Authors: Riedell PA; Hamadani M; Ahn KW; Litovich C; Brunstein CG; Cashen AF; Cohen JB; Epperla N; Hill BT; Im A
  • Sequencing of Novel Therapies for Mantle Cell Lymphoma.
    Curr Treat Options Oncol Volume: 22 Page(s): 118
    11/23/2021 Authors: Romancik JT; Cohen JB
  • Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
    Am J Hematol Volume: 96 Page(s): 1374 - 1384
    11/01/2021 Authors: Karmali R; Switchenko JM; Goyal S; Shanmugasundaram K; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ
  • Diagnostic retinal biopsy in the management of secondary non-CNS vitreoretinal lymphoma masquerading as viral retinitis: a case report.
    Int J Retina Vitreous Volume: 7 Page(s): 58
    10/11/2021 Authors: Rali A; Xu LT; Craven C; Cohen JB; Yeh S; Grossniklaus HE; O'Keefe GD
  • Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.
    Blood Adv Volume: 5 Page(s): 3623 - 3632
    09/28/2021 Authors: Orellana-Noia VM; Isaac K; Malecek M-K; Bartlett NL; Voorhees TJ; Grover NS; Hwang SR; Bennani NN; Hu R; Hill BT
  • Surveillance imaging during first remission in follicular lymphoma does not impact overall survival.
    Cancer Volume: 127 Page(s): 3390 - 3402
    09/15/2021 Authors: Goldman ML; Mao JJ; Strouse CS; Chen W; Rupji M; Chen Z; Maurer MJ; Calzada O; Churnetski M; Flowers CR
  • Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
    Leukemia Volume: 35 Page(s): 2672 - 2683
    09/01/2021 Authors: Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA
  • Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
    Eur J Haematol Volume: 107 Page(s): 301 - 310
    09/01/2021 Authors: Shanmugasundaram K; Goyal S; Switchenko J; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK; Gordon MJ
  • The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.
    Clin Cancer Res Volume: 27 Page(s): 4814 - 4824
    09/01/2021 Authors: Gordon MJ; Kaempf A; Sitlinger A; Shouse G; Mei M; Brander DM; Salous T; Hill BT; Alqahtani H; Choi M
  • American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma.
    Transplant Cell Ther Volume: 27 Page(s): 720 - 728
    09/01/2021 Authors: Munshi PN; Hamadani M; Kumar A; Dreger P; Friedberg JW; Dreyling M; Kahl B; Jerkeman M; Kharfan-Dabaja MA; Locke FL
  • Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results
    Volume: 21 Page(s): S378 - S379
    09/01/2021 Authors: Cohen JB; Shah NN; Alencar AJ; Gerson JN; Patel MR; Fahkri B; Jurczak W; Tan XN; Lewis KL; Fenske TS
  • Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Volume: 21 Page(s): S396 - S397
    09/01/2021 Authors: Santapuram P; Rupji M; Graiser M; Waller E; Blum K; Allen P; Koff J; Heffner L; Lechowicz M; Lonial S
  • Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.
    J Clin Oncol Volume: 39 Page(s): 1329 - 1338
    04/20/2021 Authors: Nowakowski GS; Hong F; Scott DW; Macon WR; King RL; Habermann TM; Wagner-Johnston N; Casulo C; Wade JL; Nagargoje GG
  • Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
    Volume: 193 Page(s): 142 - 143
    04/01/2021 Authors: Eyre T; Shah NN; Alencar A; Gerson JN; Patel MR; Fakhri B; Jurczak W; Tan X; Lewis K; Fenske T
  • Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
    Blood Adv Volume: 5 Page(s): 1648 - 1659
    03/23/2021 Authors: Merryman RW; Redd RA; Nishihori T; Chavez J; Nieto Y; Darrah JM; Rao U; Byrne MT; Bond DA; Maddocks KJ
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
    Lancet Volume: 397 Page(s): 892 - 901
    03/06/2021 Authors: Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR
  • Bendamustine, Obinutuzumab and Venetoclax As Induction Therapy for Untreated Mantle Cell Lymphoma
    Volume: 136
    11/05/2020 Authors: Greenwell IB; Switchenko JM; Maddocks KJ; Kahl BS; Craig AFM; Alizadeh AA; Allen PB; Marbury AL; Escobar A; Valla K
  • Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study
    Volume: 136
    11/05/2020 Authors: Casulo C; Love T; Lu X; Larson MC; Yost KJ; Rosenthal AC; Habermann TM; Link BK; Feldman AL; Slager SL
  • Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
    Volume: 136
    11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S
  • Ixazomib with or without Rituximab Following Immunochemotherapy and Autologous Stem Cell Transplant in Mantle Cell Lymphoma
    Volume: 136
    11/05/2020 Authors: Romancik JT; Allen PB; Waller EK; Chen Z; Valla K; Dixon K; Reagan DJ; Colbert AB; Rosand C; Palmer A
  • Is Limited-Stage Mantle Cell Lymphoma Curable and How Is It Best Managed?
    Hematol Oncol Clin North Am Volume: 34 Page(s): 849 - 859
    10/01/2020 Authors: Romancik JT; Cohen JB
  • Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
    J Clin Oncol Volume: 38 Page(s): 3095 - 3106
    09/20/2020 Authors: Jacobson CA; Hunter BD; Redd R; Rodig SJ; Chen P-H; Wright K; Lipschitz M; Ritz J; Kamihara Y; Armand P
  • Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
    Lancet Haematol Volume: 7 Page(s): e660 - e670
    09/01/2020 Authors: Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND
  • Management of Relapsed Mantle Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 20 Suppl 1 Page(s): S98 - S100
    09/01/2020 Authors: Cohen JB
  • Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma.
    Hematol Oncol Clin North Am Volume: 34 Page(s): 663 - 672
    08/01/2020 Authors: Cohen JB; Kahl BS
  • Management of Older Adults with Mantle Cell Lymphoma.
    Drugs Aging Volume: 37 Page(s): 469 - 481
    07/01/2020 Authors: Romancik JT; Cohen JB
  • Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
    Oncologist Volume: 25 Page(s): e993 - e997
    06/01/2020 Authors: Merryman RW; Carreau NA; Advani RH; Spinner MA; Herrera AF; Chen R; Tomassetti S; Ramchandren R; Hamid M; Assouline S
  • Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.
    Volume: 38
    05/20/2020 Authors: Karmali R; Switchenko JM; Goyal S; Bachanova V; Gerson J; Barta SK; Danilov AV; Grover NS; Epperla N; Burkart M
  • Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cancer Volume: 126 Page(s): 1235 - 1242
    03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM
  • A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Leuk Res Volume: 89 Page(s): 106302
    02/01/2020 Authors: Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M
  • Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
    Blood Adv Volume: 4 Page(s): 253 - 262
    01/28/2020 Authors: Torka P; Kothari SK; Sundaram S; Li S; Medeiros LJ; Ayers EC; Landsburg DJ; Bond DA; Maddocks KJ; Giri A
  • Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
    Cancer Volume: 126 Page(s): 293 - 303
    01/15/2020 Authors: Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R
  • Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Blood Volume: 134 Page(s): 1811 - 1820
    11/21/2019 Authors: Lunning M; Vose J; Nastoupil L; Fowler N; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB
  • The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient.
    Oncology (Williston Park) Volume: 33
    11/14/2019 Authors: Blanquicett C; Cohen JB; Flowers C; Johnson T
  • Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
    Volume: 134
    11/13/2019 Authors: Orellana-Noia VM; Isaac K; Wages NA; Malecek M-K; Bartlett NL; Voorhees TJ; Grover NS; Hwang SR; Bennani NN; Hu R
  • Curriculum in Chronic Lymphocytic Leukemia Narrows the Educational Gaps of the Oncology Healthcare Team
    Volume: 134
    11/13/2019 Authors: Willis L; Brauer L; Van Laar ES; Kugel P; Lucero KS; Allan JN; Awan FT; Brander DM; Cohen JB; Barrientos JC
  • Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab
    Volume: 134
    11/13/2019 Authors: Friedberg JW; Brady MT; Strawderman M; Kahl BS; Leonard JP; Lossos IS; Flowers CR; Sutamtewagul G; Cohen JB; Peterson DR
  • A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
    Volume: 134
    11/13/2019 Authors: Cohen JB; Portell CA; Hamadani M; Jegede O; Diefenbach C; David KA; Fletcher CD; Landsburg DJ; Kahl BS
  • Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
    Volume: 134
    11/13/2019 Authors: Epperla N; Costa LJ; Vaughn JL; Hanel W; Raya S; Cashen AF; Sarmad R; Badar T; Hamadani M; Liu Y
  • A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents: Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life
    Volume: 134
    11/13/2019 Authors: Ujjani C; Mato AR; Cohen JB; Svoboda J; Andorsky D; Goy A; Wang ML; Kumar A; Torney PA; Dawson M
  • Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center Analysis
    Volume: 134
    11/13/2019 Authors: Winter AM; Wei W; Ayers EC; Landsburg DJ; Raya S; Kahl BS; Rogers A; Maddocks KJ; Khan M; Kittai AS
  • Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Epperla N; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
  • The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Romancik J; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
  • Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
    Volume: 134
    11/13/2019 Authors: Cohen JB; Switchenko JM; Shanmugasundaram K; Goyal S; Calzada O; Churnetski MC; Kolla B; Bachanova V; Gerson JN; Barta SK
  • Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
    Volume: 134
    11/13/2019 Authors: Merryman RW; Castagna L; Corradini P; Ho VT; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Herrera AF
  • NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR FOLLOW-UP IN THE CHECKMATE 205 STUDY
    Volume: 104 Page(s): 21 - 22
    10/21/2019 Authors: Domingo-Domenech E; Ramchandren R; Rueda A; Trne; Ny M; Feldman T; Hun LJ; Provencio M; Sillaber C; Cohen JB
  • Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
    Biol Blood Marrow Transplant Volume: 25 Page(s): 1859 - 1868
    09/01/2019 Authors: Ahmed S; Kanakry JA; Ahn KW; Litovich C; Abdel-Azim H; Aljurf M; Bacher VU; Bejanyan N; Cohen JB; Farooq U
  • Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
    J Clin Oncol Volume: 37 Page(s): 1997 - 2007
    08/10/2019 Authors: Ramchandren R; Domingo-Domnech E; Rueda A; Trnn M; Feldman TA; Lee HJ; Provencio M; Sillaber C; Cohen JB; Savage KJ
  • Racial and Socioeconomic Disparities in Mantle Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 19 Page(s): e312 - e320
    06/01/2019 Authors: Shah NN; Xi Y; Liu Y; Koff JL; Flowers CR; Behera M; Cohen JB
  • Impact on survival of surveillance imaging after first remission in follicular lymphoma.
    Volume: 37
    05/20/2019 Authors: Mao J; Strouse CS; Goldman M; Chen W; Chen Z; Maurer MJ; Calzada O; Churnetski M; Flowers C; Cerhan JR
  • Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin.
    Volume: 60 Page(s): 940 - 946
    04/01/2019 Authors: Badar T; Hamadani M; Bachanova V; Maddocks KJ; Umyarova E; Chavez JC; Epperla N; Chhabra S; Xavier AC; Karmali R
  • When to use stem cell transplant in mantle cell lymphoma.
    Expert Rev Hematol Volume: 12 Page(s): 207 - 210
    04/01/2019 Authors: Greenwell IB; Cohen JB
  • Prognostic Variables of Progression Free Survival in Mantle Cell Lymphoma after Autologous Stem Cell Transplantation
    Volume: 25
    03/01/2019 Authors: Churnetski MC; Switchenko JM; Goyal S; Shanmugasundaram K; Calzada O; Kolla B; Bachanova V; Gerson JN; Barta SK; Maldonado E
  • Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
    J Clin Oncol Volume: 37 Page(s): 481 - 489
    02/20/2019 Authors: Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N
  • Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
    J Clin Oncol Volume: 37 Page(s): 471 - 480
    02/20/2019 Authors: Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang MI; Cohen JB; Calzada O
  • Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.
    Lancet Haematol Volume: 6 Page(s): e100 - e109
    02/01/2019 Authors: Nastoupil LJ; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S
  • Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.
    Volume: 19 Page(s): 89 - 94
    02/01/2019 Authors: Hall KH; Valla K; Flowers CR; Cohen JB
  • Safety and preliminary efficacy of ACTR707, autologous T lymphocytes expressing an antibody-coupled T-cell receptor, in combination with rituximab in subjects with relapsed or refractory CD20-positive B-cell lymphoma
    Volume: 7
    02/01/2019 Authors: Bachanova V; Cohen J; Akard L; Jaglowski S; Sachs J; Ranger A; Harris P; McGinness K; Motz G; Flinn I
  • Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Br J Haematol Volume: 184 Page(s): 524 - 535
    02/01/2019 Authors: Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P
  • Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    J Hematol Oncol Volume: 12 Page(s): 6
    01/10/2019 Authors: Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO
  • Nivolumab plus Doxorubicin, Vinblastine and Dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: CheckMate 205 Cohort D 2-year follow-up results
    Volume: 42 Page(s): 162 - 162
    01/01/2019 Authors: Engert A; Domingo-Domenech E; Ramchandren R; Rueda A; Trneny M; Feldman T; Lee HJ; Provencio M; Sillaber C; Cohen JB
  • The association of physical activity before and after lymphoma diagnosis with survival outcomes.
    Am J Hematol Volume: 93 Page(s): 1543 - 1550
    12/01/2018 Authors: Pophali PA; Ip A; Larson MC; Rosenthal AC; Maurer MJ; Flowers CR; Link BK; Farooq U; Feldman AL; Allmer C
  • Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.
    Leuk Lymphoma Volume: 59 Page(s): 2862 - 2870
    12/01/2018 Authors: Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover N; Mathews S; Park SI; Gordon M; Danilov A; Epperla N
  • Novel therapies for relapsed/refractory aggressive lymphomas.
    Hematology Am Soc Hematol Educ Program Volume: 2018 Page(s): 75 - 82
    11/30/2018 Authors: Cohen JB
  • Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy
    Volume: 132
    11/29/2018 Authors: Ayers EC; Li S; Medeiros J; Bond DA; Maddocks KJ; Torka P; Hicks AM; Curry M; Wagner-Johnston ND; Karmali R
  • Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers
    Volume: 132
    11/29/2018 Authors: Kothari SK; Li S; Medeiros LJ; Ayers EC; Landsburg DJ; Bond DA; Maddocks KJ; Giri A; Hess BT; Pham LQ
  • Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F)
    Volume: 132
    11/29/2018 Authors: Hong F; Thanarajasingam G; Ansell SM; Ambinder RF; Cohen JB; Robertson M; David KA; Advani RH; Fenske TS; Barta SK
  • A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I)
    Volume: 132
    11/29/2018 Authors: Diefenbach C; Hong F; Ambinder RF; Cohen JB; Robertson M; David KA; Advani RH; Fenske TS; Barta SK; Palmisano N
  • Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.
    J Clin Oncol Page(s): JCO1800359
    10/25/2018 Authors: Davids MS; von Keudell G; Portell CA; Cohen JB; Fisher DC; Foss F; Roberts AW; Seymour JF; Humerickhouse RA; Tam CS
  • Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
    Cancer Volume: 124 Page(s): 3192 - 3200
    08/01/2018 Authors: Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE
  • Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Cancer Volume: 124 Page(s): 2306 - 2315
    06/01/2018 Authors: Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ
  • Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis.
    Biol Blood Marrow Transplant Volume: 24 Page(s): 1163 - 1171
    06/01/2018 Authors: Casulo C; Friedberg JW; Ahn KW; Flowers C; DiGilio A; Smith SM; Ahmed S; Inwards D; Aljurf M; Chen AI
  • Effect of concurrent CYP3A4 interacting medications on ibrutinib outcomes in patients with CLL.
    Volume: 36
    05/20/2018 Authors: Kittai A; Maniar A; Gordon MJ; Churnetski M; Rivera X; Alqahtani H; Hoff S; Rice D; Rice G; Persky DO
  • Outcomes in non-Hodgkin lymphoma by Latino country-of-origin (COO).
    Volume: 36
    05/20/2018 Authors: Calzada O; Xi Y; Behera M; Koff JL; Flowers C; Liu Y; Cohen JB
  • Racial and socioeconomic disparities in mantle cell lymphoma.
    Volume: 36
    05/20/2018 Authors: Shah N; Liu Y; Xi Y; Flowers C; Koff JL; Behera M; Cohen JB
  • Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
    Volume: 36
    05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
  • Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.
    Volume: 36
    05/20/2018 Authors: Diefenbach CSM; Hong F; Ambinder RF; Cohen JB; David KA; Advani RH; Robertson MJ; Fenske TS; Barta SK; Palmisano N
  • Multi-center retrospective study evaluating outcomes of grade 3A follicular lymphoma (FL).
    Volume: 36
    05/20/2018 Authors: Greene K; Phillips TJ; Danilov AV; Byrne MT; Cohen JB; Kamdar MK; Peres-da-Silva A; Churnetski I; Pan Z; Danielson NC
  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
    J Clin Oncol Volume: 36 Page(s): 1428 - 1439
    05/10/2018 Authors: Armand P; Engert A; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R; Cohen JB
  • Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    J Clin Oncol Volume: 36 Page(s): 942 - 950
    04/01/2018 Authors: Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A
  • Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study
    Volume: 181 Page(s): 87 - 88
    04/01/2018 Authors: Cohen JB; Engert A; Ansell SM; Younes A; Trneny M; Savage KJ; Ramchandren R; Collins GP; Fanale MA; Armand P
  • Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.
    Leuk Lymphoma Volume: 59 Page(s): 888 - 895
    04/01/2018 Authors: Guidot DM; Switchenko JM; Nastoupil LJ; Koff JL; Blum KA; Maly J; Flowers CR; Cohen JB
  • Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
    Volume: 24 Page(s): S135 - S136
    03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S
  • Effect of physical activity (PA) before and after diagnosis on overall survival (OS) for patients (pts) with lymphoma.
    Volume: 36
    03/01/2018 Authors: Ip A; Pophali PA; Larson MC; Rosenthal AC; Maurer MJ; Link BK; Farooq U; Feldman AL; Allmer C; Slager SL
  • R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Br J Haematol Volume: 180 Page(s): 534 - 544
    02/01/2018 Authors: Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE
  • Nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from Cohort D of the phase 2 CheckMate 205 study
    Volume: 41 Page(s): 273 - 273
    01/01/2018 Authors: Engert A; Domingo Domenech E; Rueda A; Armand P; Trneny M; Feldman T; Ansell S; Provencio M; Jaeger U; Cohen JB
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.
    Hematol Oncol Volume: 35 Page(s): 528 - 535
    12/01/2017 Authors: Epperla N; Hamadani M; Cashen AF; Ahn KW; Oak E; Kanate AS; Calzada O; Cohen JB; Farmer L; Ghosh N
  • C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
    Cancer Volume: 123 Page(s): 4411 - 4418
    11/15/2017 Authors: Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M
  • TP53 mutations in MCL: more therapy is not better.
    Blood Volume: 130 Page(s): 1876 - 1877
    10/26/2017 Authors: Cohen JB
  • Association of Complex Karyotype with Inferior Survival in Mantle Cell Lymphoma is Independent of Specific Cytogenetic Abnormalities
    Volume: 17 Page(s): S377 - S377
    09/01/2017 Authors: Greenwell IB; Staton AD; Lee M; Switchenko JM; Maly J; Blum K; Grover N; Mathews S; Park S; Gordon M
  • Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial
    Volume: 40 Page(s): 13 - +
    09/01/2017 Authors: Jaeger U; Engert A; Fanale M; Santoro A; Armand P; Ansell S; Zinzani PL; Timmerman JM; Collins GP; Ramchandren R
  • Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
    Volume: 17 Page(s): S326 - S327
    09/01/2017 Authors: Carlo-Stella C; Collins GP; Armand P; Zinzani PL; Cohen JB; Halwani A; Millenson M; Provencio M; Domingo Domenech E; Giulino-Roth L
  • A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
    Leuk Lymphoma Volume: 58 Page(s): 1 - 2
    09/01/2017 Authors: Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
  • Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.
    J Clin Oncol Volume: 35 Page(s): 2260 - 2267
    07/10/2017 Authors: Landsburg DJ; Falkiewicz MK; Maly J; Blum KA; Howlett C; Feldman T; Mato AR; Hill BT; Li S; Medeiros LJ
  • Allogeneic hematopoietic stem cell transplantation outcomes after nivolumab monotherapy for plus relapsed/refractory hodgkin lymphoma (CheckMate 039 and CheckMate 205)
    Volume: 52 Page(s): S15 - S16
    07/01/2017 Authors: Carlo-Stella C; Collins G; Armand P; Zinzani PL; Cohen JB; Halwani A; Millenson M; Provencio M; Domingo Domenech E; Giulino-Roth L
  • CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
    Volume: 102 Page(s): 312 - 312
    06/26/2017 Authors: Nastoupil L; Lunning MA; Vose JM; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB; Burger JA; Wierda WG; O'Brien S
  • NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
    Volume: 102 Page(s): 145 - 145
    06/26/2017 Authors: Engert A; Fanale M; Santoro A; Armand P; Ansell S; Zinzani PL; Timmerman J; Collins G; Ramchandren R; Cohen J
  • Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL.
    Volume: 35
    05/20/2017 Authors: Nastoupil LJ; Lunning MA; Vose J; Schreeder MT; Siddiqi T; Flowers C; Cohen JB; Burger JA; Wierda WG; O'Brien SM
  • MYC plus relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.
    Volume: 35
    05/20/2017 Authors: Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy NM; Karmali R; Umyarova E; Bachanova V; Glenn MJ; Xavier AC
  • Outcomes in Mantle Cell Lymphoma for Elderly Patients Undergoing Autologous Stem Cell Transplant in CR1
    Volume: 23 Page(s): S215 - S216
    03/01/2017 Authors: Greenwell IB; Valla K; Caulfield S; Switchenko JM; Staton A; Flowers C; Maly J; Blum KA; Grover N; Mathews S
  • Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Expert Rev Anticancer Ther Volume: 17 Page(s): 271 - 279
    03/01/2017 Authors: Greenwell IB; Flowers CR; Blum KA; Cohen JB
  • Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma.
    Blood Volume: 129 Page(s): 561 - 564
    02/02/2017 Authors: Cohen JB; Behera M; Thompson CA; Flowers CR
  • Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
    Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
    01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR
  • Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
    Am Soc Clin Oncol Educ Book Volume: 37 Page(s): 512 - 525
    01/01/2017 Authors: Cohen JB; Zain JM; Kahl BS
  • Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma
    Volume: 128
    12/02/2016 Authors: Portell CA; Chen RW; Wages N; Cohen JB; Weber MJ; Petroni G; Kahl BS; Williams ME
  • Benefit of Consolidative Autologous Stem Cell Transplantation in First Complete Remission for Patients with Double Hit Lymphoma Appears Dependent on Induction Regimen Intensity
    Volume: 128
    12/02/2016 Authors: Landsburg DJ; Reddy N; Howlett C; Feldman T; Mato AR; Kaplan JB; Behdad A; Petrich AM; Maly J; Blum K
  • Prolonged Progression-Free Survival Is Possible in Patients with Diffuse Large B-Cell Lymphoma Receiving > 1 Salvage Therapies before Autologous Stem Cell Transplant
    Volume: 128
    12/02/2016 Authors: Kettle AG; Switchenko J; Calzada O; Anh TP; Farone M; Graiser M; Flowers CR; Cohen JB
  • CD30 Expression Is Not Acquired at Time of Relapse in Diffuse Large B-Cell Lymphoma
    Volume: 128
    12/02/2016 Authors: Calzada O; Bradley KT; Switchenko J; Staton AD; Koff JL; Flowers CR; Cohen JB
  • An Evaluation of the Role of Surveillance Imaging in Mantle Cell Lymphoma in First Remission
    Volume: 128
    12/02/2016 Authors: Guidot DM; Switchenko J; Nastoupil LJ; Koff JL; Flowers C; Cohen JB
  • Risk Stratification of Untreated Mantle Cell Lymphoma Patients Using MIPI, Ki67 Proliferative Index and Cytogenetics
    Volume: 128
    12/02/2016 Authors: Staton AD; Greenwell IB; Switchenko JM; Maly J; Blum K; Grover NS; Mathews S; Park SI; Gordon MJ; Danilov AV
  • a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Volume: 128
    12/02/2016 Authors: Maddocks KJ; Cohen JB; Huang Y; Christian BA; Benson DM; Jones J; Flowers C; Heffner LT; Jenkins C; Sexton J
  • Primary Failure Diffuse Large B Cell Lymphoma: Early Autologous or Donor Hematopoietic Cell Transplantation Not Effective in Patients with Ultra-High Risk Features
    Volume: 128
    12/02/2016 Authors: Costa LJ; Reddy N; Maddocks KJ; Epperla N; Karmali R; Bachanova V; Umyarova E; Zhou Z; Glenn M; Chavez JC
  • CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Volume: 101 Page(s): 43 - 44
    10/01/2016 Authors: Zinzani PL; Engert A; Younes A; Santoro A; Ansell S; Timmerman J; Collins G; Armand P; Savage KJ; Trneny M
  • A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
    Volume: 101 Page(s): 44 - 45
    10/01/2016 Authors: Diefenbach CSM; Hong F; Ambinder RF; Cohen JB; Robertson MJ; Fenske TS; Advani R; Kahl BS; Ansell S
  • Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.
    Biol Blood Marrow Transplant Volume: 22 Page(s): 1543 - 1551
    09/01/2016 Authors: Fenske TS; Hamadani M; Cohen JB; Costa LJ; Kahl BS; Evens AM; Hamlin PA; Lazarus HM; Petersdorf E; Bredeson C
  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Lancet Oncol Volume: 17 Page(s): 1283 - 1294
    09/01/2016 Authors: Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J
  • Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
    Volume: 122 Page(s): 2356 - 2363
    08/01/2016 Authors: Cohen JB; Han X; Jemal A; Ward EM; Flowers CR
  • CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN
    Volume: 101 Page(s): 319 - 319
    06/01/2016 Authors: Engert A; Santoro A; Shipp M; Zinzani PL; Timmerman J; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J
  • De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
    Am J Hematol Volume: 91 Page(s): 395 - 399
    06/01/2016 Authors: Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F
  • Deferred treatment as a viable option for selected patients with mantle cell lymphoma.
    Volume: 34
    05/20/2016 Authors: Calzada O; Switchenko JM; Maly JJ; Blum KA; Grover NS; Mathews S; Park SI; Gordon MJ; Danilov AV; Flowers C
  • Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.
    Volume: 34
    05/20/2016 Authors: Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Maly JJ; Blum KA; Grover NS; Mathews S; Park SI; Gordon M
  • Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).
    Volume: 34
    05/20/2016 Authors: Epperla N; Hamadani M; Ahn KW; Oak E; Cashen AF; Kanate AS; Calzada O; Farmer ZL; Tallarico M; Nabhan C
  • GIFT4 fusokine converts leukemic B cells into immune helper cells.
    J Transl Med Volume: 14 Page(s): 106
    04/27/2016 Authors: Deng J; Pennati A; Cohen JB; Wu Y; Ng S; Wu JH; Flowers CR; Galipeau J
  • A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management.
    J Oncol Pract Volume: 12 Page(s): 232 - 238
    03/01/2016 Authors: Staton AD; Cohen JB
  • Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
    Bone Marrow Transplant Volume: 51 Page(s): 58 - 66
    01/01/2016 Authors: Klyuchnikov E; Bacher U; Woo Ahn K; Carreras J; Krger NM; Hari PN; Ku GH; Ayala E; Chen AI; Chen Y-B
  • Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412)
    Volume: 126
    12/03/2015 Authors: Diefenbach CS; Hong F; Cohen JB; Robertson MJ; Ambinder RF; Fenske TS; Advani RH; Kahl BS; Ansell S
  • Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
    Volume: 126
    12/03/2015 Authors: Lunning MA; Vose J; Fowler N; Nastoupil L; Burger JA; Wierda W; Schreeder MT; Siddiqi T; Flowers C; Cohen JB
  • A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
    Volume: 126
    12/03/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston A; Flowers C; Devine SM; Blum KA
  • A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL)
    Volume: 126
    12/03/2015 Authors: Maddocks KJ; Cohen JB; Christian BA; Benson DM; Blum KA
  • Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant
    Volume: 126
    12/03/2015 Authors: Lee MJ; Switchenko J; Thomas JS; Koff JL; Nastoupil L; Lechowicz MJ; Langston AA; Flowers C; Cohen JB
  • Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma
    Volume: 126
    12/03/2015 Authors: Chandra P; Akinbobuyi O; Liao A; Arora J; Chen Z; Lechowicz MJ; Langston AA; Kowalsky J; Cohen JB; Flowers CR
  • Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
    Biol Blood Marrow Transplant Volume: 21 Page(s): 2091 - 2099
    12/01/2015 Authors: Klyuchnikov E; Bacher U; Krger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A
  • A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 694 - 698
    11/01/2015 Authors: Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK
  • A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma.
    Bone Marrow Transplant Volume: 50 Page(s): 1416 - 1423
    11/01/2015 Authors: Satwani P; Ahn KW; Carreras J; Abdel-Azim H; Cairo MS; Cashen A; Chen AI; Cohen JB; Costa LJ; Dandoy C
  • A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Volume: 171 Page(s): 539 - 546
    11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ
  • GIFT4-reprogrammed leukemic B cells for CLL immunotherapy.
    Volume: 21
    09/01/2015 Authors: Deng J; Cohen J; Pennati A; Wu Y; Yuan S; Flowers C; Galipeau J
  • Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
    09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A
  • Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma.
    Biol Blood Marrow Transplant Volume: 21 Page(s): 1605 - 1611
    09/01/2015 Authors: Bachanova V; Burns LJ; Ahn KW; Laport GG; Akpek G; Kharfan-Dabaja MA; Nishihori T; Agura E; Armand P; Jaglowski SM
  • A Plethora of Novel Therapies--Which One to Choose?
    Oncology (Williston Park) Volume: 29 Page(s): 499 - 500
    07/01/2015 Authors: Cohen JB; Flowers CR
  • UBLITUXIMAB + TGR-1202 DEMONSTRATES ACTIVITY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NHL AND HIGH-RISK CLL
    Volume: 100 Page(s): 110 - 111
    06/01/2015 Authors: Lunning MA; Vose JM; Fowler NH; Nastoupil L; Burger JA; Wierda WG; Schreeder MT; Siddiqi T; Flowers CR; Cohen JB
  • A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412).
    Volume: 33
    05/20/2015 Authors: Diefenbach CSM; Li H; Kahl BS; Robertson MJ; Cohen J; Advani RH; Ambinder R; Fenske TS; Ansell SM
  • A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
    Volume: 33
    05/20/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston AA; Flowers C; Devine SM; Blum KA
  • Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies.
    Volume: 33
    05/20/2015 Authors: Fowler NH; Nastoupil LJ; Lunning MA; Vose J; Siddiqi T; Flowers C; Cohen JB; Schreeder MT; Miguel M; Blumel S
  • Ublituximab plus TGR-1202 activity and safety profile in relapsed/refractory B-cell NHL and high-risk CLL
    Volume: 33
    05/20/2015 Authors: Lunning MA; Vose J; Fowler NH; Nastoupil LJ; Schreeder MT; Siddiqi T; Flowers C; Cohen JB; Blumel S; Miguel M
  • Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 278 - 285.e1
    05/01/2015 Authors: Cohen JB; Ruppert AS; Heerema NA; Andritsos LA; Jones JA; Porcu P; Baiocchi R; Christian BA; Byrd JC; Flynn J
  • Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 270 - 277
    05/01/2015 Authors: Davis CC; Cohen JB; Shah KS; Hutcherson DA; Surati MJ; Valla K; Panjic EH; Handler CE; Switchenko JM; Flowers CR
  • Role of allogeneic stem cell transplantation in mantle cell lymphoma.
    Eur J Haematol Volume: 94 Page(s): 290 - 297
    04/01/2015 Authors: Cohen JB; Burns LJ; Bachanova V
  • Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era.
    Leuk Lymphoma Volume: 56 Page(s): 557 - 558
    03/01/2015 Authors: Flowers CR; Cohen JB; Khan MK
  • Next-generation surveillance strategies for patients with lymphoma.
    Future Oncol Volume: 11 Page(s): 1977 - 1991
    01/01/2015 Authors: Cohen JB; Kurtz DM; Staton AD; Flowers CR
  • A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)
    BLOOD Volume: 124
    12/06/2014 Authors: Maddocks KJ; Cohen JB; Christian B; Flynn JM; Jaglowski SM; Blum KA
  • Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis
    Volume: 124
    12/06/2014 Authors: Howlett C; Landsburg DJ; Chong EA; Snedecor SJ; Schuster SJ; Green TM; Cohen JB; Svoboda J; Nasta SD; Feldman T
  • Optimal disease surveillance strategies in non-Hodgkin lymphoma.
    Hematology Am Soc Hematol Educ Program Volume: 2014 Page(s): 481 - 487
    12/05/2014 Authors: Cohen JB; Flowers CR
  • Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms.
    Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): 460 - 467.e2
    12/01/2014 Authors: Read JA; Koff JL; Nastoupil LJ; Williams JN; Cohen JB; Flowers CR
  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
    Blood Volume: 124 Page(s): 2354 - 2361
    10/09/2014 Authors: Petrich AM; Gandhi M; Jovanovic B; Castillo JJ; Rajguru S; Yang DT; Shah KA; Whyman JD; Lansigan F; Hernandez-Ilizaliturri FJ
  • Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival.
    Cancer Volume: 120 Page(s): 1677 - 1685
    06/01/2014 Authors: Cohen JB; Geyer SM; Lozanski G; Zhao W; Heerema NA; Hall NC; Nagar VA; Hemminger JA; Jones JA; Porcu P
  • Simplified Technique for Administration of High Dose Melphalan
    Volume: 20 Page(s): S291 - S292
    02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A
  • Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma.
    Bone Marrow Transplant Volume: 48 Page(s): 1212 - 1217
    09/01/2013 Authors: Cohen JB; Hall NC; Ruppert AS; Jones JA; Porcu P; Baiocchi R; Christian BA; Penza S; Benson DM; Flynn J
  • Peripheral T-cell lymphoma: what's the role for transplant?
    Oncology (Williston Park) Volume: 27 Page(s): 891 - 892
    09/01/2013 Authors: Cohen JB; Flowers CR
  • Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics
    Volume: 19 Page(s): S320 - S321
    02/01/2013 Authors: Cohen JB; McBride A; Geyer S; Bingman A; Elder P; Blum W; Klisovic R; Penza S; Andritsos LA; Benson DM
  • COMPLEX KARYOTYPE (CK) IS ASSOCIATED WITH INCREASED CUMULATIVE INCIDENCE OF RELAPSE (CIR) FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MANTLE CELL LYMPHOMA (MCL) IN FIRST REMISSION
    Volume: 18 Page(s): S205 - S206
    02/01/2012 Authors: Cohen JB; Ruppert AS; Kaplan LD; Baiocchi R; Porcu P; Flynn J; Penza S; Jones JA; Blum KA; Devine SM
  • Hearing Loss due to Infiltration of the Tympanic Membrane by Chronic Lymphocytic Leukemia.
    Case Rep Hematol Volume: 2012 Page(s): 589718
    01/01/2012 Authors: Cohen JB; Cavaliere R; Byrd JC; Andritsos LA
  • Evaluation and management of lymphoma and leukemia in pregnancy.
    Clin Obstet Gynecol Volume: 54 Page(s): 556 - 566
    12/01/2011 Authors: Cohen JB; Blum KA
  • The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma
    Volume: 118 Page(s): 1345 - 1346
    11/18/2011 Authors: Cohen JB; Hall N; Ruppert AS; Jones JA; Porcu P; Baiocchi RA; Penza S; Benson DM; Andritsos LA; Flynn JM
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements